Elevance Health raises 2026 EPS forecast but profit margin recovery remains uncertain

Elevance Health increased its adjusted EPS guidance for 2026 to at least $29, reflecting optimism about earnings growth. However, despite a 15.9% rise in third-quarter adjusted EPS, the company's nine-month operating gain fell by 25.7%, indicating ongoing challenges in profitability. Health Benefits margins, especially in Medicaid, continue to face pressure despite better medical cost trends and stronger quarterly results. The company's valuation discount and solid capital returns support a Hold rating until there is clearer evidence of sustained margin recovery and earnings growth.

Elevance Health shares trade at USD 437.06 on Pluang as of Oct 22, 2026 11:11 WIB, down 0.71% for the day. The stock's market cap stands at $95.46 billion with a dividend yield of 1.56%. Investors hold shares typically for 8 days, reflecting moderate trading interest amid mixed earnings signals.